MAP PHARMACEUTICALS, INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 23 rows in 2012. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2012-11-23: Reporting owner HENWOOD GERALDINE; Form 4; Security Stock Option; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2012-11-23: Reporting owner HENWOOD GERALDINE; Form 4; Security Stock Option; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2012-11-01: Reporting owner GIANAKAKOS ANASTASIOS; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2012-05-17: Reporting owner Wolff Henry Ward; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2012-11-23 | HENWOOD GERALDINE Director | 4 | Stock Option Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,490 0 owned after | $0.74 exercise price | 2012-11-27 | |
| 2012-11-23 | HENWOOD GERALDINE Director | 4 | Stock Option Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,750 0 owned after | $3.18 exercise price | 2012-11-27 | |
| 2012-11-01 | GIANAKAKOS ANASTASIOS Officer (SVP, Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,767 0 owned after | $6.39 exercise price | 2012-11-05 | |
| 2012-05-17 | Wolff Henry Ward Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $11.69 exercise price | 2012-05-21 | |
| 2012-05-17 | WARD SCOTT R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $11.69 exercise price | 2012-05-21 | |
| 2012-05-17 | HENWOOD GERALDINE Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $11.69 exercise price | 2012-05-21 | |
| 2012-05-17 | KELLEY BERNARD J Director | 4 | Stock Option (right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $11.69 exercise price | 2012-05-21 | |
| 2012-05-17 | MCPHERRON MATTHEW V Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $11.69 exercise price | 2012-05-18 | |
| 2012-04-02 | GIANAKAKOS ANASTASIOS Officer (SVP, Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,500 5,767 owned after | $6.39 exercise price | 2012-04-04 | |
| 2012-03-09 | GIANAKAKOS ANASTASIOS Officer (SVP, Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 8,267 owned after | $6.39 exercise price | 2012-03-13 | |
| 2012-03-09 | Friedman Charlene A Officer (SVP, Gen Counsel & Sec) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 22,328 owned after | $12.37 exercise price | 2012-03-13 | |
| 2012-02-21 | GIANAKAKOS ANASTASIOS Officer (SVP & Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,115 18,267 owned after | $6.39 exercise price | 2012-02-22 | |
| 2012-02-21 | GIANAKAKOS ANASTASIOS Officer (SVP & Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,385 0 owned after | $6.39 exercise price | 2012-02-22 | |
| 2012-02-06 | GIANAKAKOS ANASTASIOS Officer (SVP & Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 0 owned after | $6.39 exercise price | 2012-02-07 | |
| 2012-01-25 | ARMER THOMAS A Director, Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +32,500 32,500 owned after | $14.09 exercise price | 2012-01-27 | |
| 2012-01-25 | KELLERMAN DONALD J Officer (SVP,Clinical Dev & Med Affairs) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +32,500 32,500 owned after | $14.09 exercise price | 2012-01-27 | |
| 2012-01-25 | GIANAKAKOS ANASTASIOS Officer (SVP & Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +32,500 32,500 owned after | $14.09 exercise price | 2012-01-27 | |
| 2012-01-25 | NELSON TIMOTHY S Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +112,500 112,500 owned after | $14.09 exercise price | 2012-01-27 | |
| 2012-01-25 | Borland Scott Officer (SVP, Neurology Franchise) | 4 | Stock Option (Right to Buy) Derivative · Indirect · See footnote | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +35,500 35,500 owned after | $14.09 exercise price | 2012-01-27 | |
| 2012-01-25 | CHAI CHRISTOPHER Y Officer (SVP & CFO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +32,500 32,500 owned after | $14.09 exercise price | 2012-01-27 | |
| 2012-01-25 | Friedman Charlene A Officer (SVP President, Gen Counsel&Sec) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +32,500 32,500 owned after | $14.09 exercise price | 2012-01-27 | |
| 2012-01-19 | GIANAKAKOS ANASTASIOS Officer (SVP & Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,471 0 owned after | $0.74 exercise price | 2012-01-20 | |
| 2012-01-13 | OSHEA WILLIAM J Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,000 20,000 owned after | $13.79 exercise price | 2012-01-17 |